Aileron Therapeutics pulled a hard pivot in 2023, merging with Lung Therapeutics to gain a new pipeline and investor base. | ...

We recently compiled a list of the 15 Best Large-Cap Value Stocks to Buy in 2025. In this article, we are going to take a ...

An Eli Lilly logo is seen on the side of a building in November 2021.

We recently compiled a list of the 12 Safest Stocks to Buy According to Hedge Funds. In this article, we are going to take a ...

“The problem with the Alzheimer’s group is they were very co-opted,” said Peter J. Whitehouse, MD, PhD, a professor of ...

With the inclusion of Franklin College as a National Register Historic District, Johnson County now has eight such districts.

Amphista Therapeutics appoints Paul Medeiros as Chief Business OfficerAppointment supports the Company’s ambitions to advance ...

Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh® (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn's ...

Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...

Zepbound, as expected, was more effective in promoting weight loss. Eli Lilly's Zepbound drug holds potential to dominate the global obesity market due to its superior efficacy and strategic ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.

In this article, we are going to take a look at where Eli Lilly And Co. (NYSE:LLY) stands against other stocks that could split in the near future. Stock splits don’t change how much a company ...